Chang Ho Ahn
Director/Board Member chez TheraTarget, Inc.
Profil
Chang Ho Ahn was the founder and had founded Rexahn Pharmaceuticals, Inc. in 2001, where he held the title of Chairman & Chief Scientist from 2013 to 2015.
He is currently a Director at TheraTarget, Inc. Dr. Ahn's former positions include Chairman & CEO at Rexahn Corp.
from 2001 to 2005, President at The Society of Biomedical Research from 2000 to 2003, and Expert Regulatory Officer & Laboratory Head at Center for Drug Evaluation & Research from 1988 to 2001.
Dr. Ahn's education includes an undergraduate degree from Creighton University, a doctorate degree from The Ohio State University in 1985, and an undergraduate degree from Seoul National University.
Postes actifs de Chang Ho Ahn
| Sociétés | Poste | Début |
|---|---|---|
TheraTarget, Inc.
 TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT. | Director/Board Member | - |
Anciens postes connus de Chang Ho Ahn
| Sociétés | Poste | Fin |
|---|---|---|
| REXAHN PHARMACEUTICALS, INC. | Founder | 31/08/2017 |
| Rexahn Corp. | Chief Executive Officer | 01/05/2005 |
| The Society of Biomedical Research | President | 01/01/2003 |
| Center for Drug Evaluation & Research | Corporate Officer/Principal | 01/01/2001 |
Formation de Chang Ho Ahn
| Creighton University | Undergraduate Degree |
| The Ohio State University | Doctorate Degree |
| Seoul National University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
| Rexahn Corp. | Finance |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
| The Society of Biomedical Research | |
| Center for Drug Evaluation & Research | Government |
TheraTarget, Inc.
TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT. | Health Technology |
